Mosunetuzumab and Polatuzumab Vedotin for Untreated Follicular Lymphoma
Mosunetuzumab and Polatuzumab Vedotin for Untreated Follicular Lymphoma
Active, not recruiting · NCT05410418 · Registry updated 2025-12-15Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Mosunetuzumab and Polatuzumab Vedotin for Untreated Follicular Lymphoma | B-cell neoplasm, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, follicular lymphoma, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, neoplasm | Active, not recruiting | Phase 2 | 2025-12-15 | NCT05410418 |
3 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Genentech, Inc. | 221 |
| Institute for Follicular Lymphoma | 1 |
| Washington University School of Medicine | 475 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Washington University School of Medicine | St Louis | United States | 895 |